Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice

Gut

Volumn 64, Issue 12, 2015, Pages 1905-1912

  Kortüm, Benedikt ^a   Campregher, Christoph ^a   Lang, Michaela ^a   Khare, Vineeta ^a   Pinter, Matthias ^a   Evstatiev, Rayko ^a   Schmid, Gerald ^a   Mittlböck, Martina ^a   Scharl, Theresa ^b   Kucherlapati, Melanie H ^c   Edelmann, Winfried ^d   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; MESALAZINE; PROTEIN MSH2; THYMOQUINONE; VILLIN; BENZOQUINONE DERIVATIVE; MSH2 PROTEIN, MOUSE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE CARCINOMA; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MODEL; DRUG EFFECTS; FRAMESHIFT MUTATION; GENETICS; HCT 116 CELL LINE; INTESTINE MUCOSA; METABOLISM; MICROSATELLITE INSTABILITY; MUTATION RATE; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOQUINONES; CELL PROLIFERATION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MODELS, ANIMAL; FEMALE; FRAMESHIFT MUTATION; HCT116 CELLS; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; MICE; MICROSATELLITE INSTABILITY; MUTATION RATE; MUTS HOMOLOG 2 PROTEIN; TUMOR BURDEN;

EID: 84954271494     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307663     Document Type: Article

References (43)

1. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.e3.
2. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004;20:269-76.
3. Nagasaka T, Rhees J, Kloor M, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 2010;70:3098-108.
4. Kunkel TA, Bebenek K. DNA replication fidelity. Annu Rev Biochem 2000;69:497-529.
5. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18.
6. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999;36:801-18.
7. Chung H, Young DJ, Lopez CG, et al. Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PloS ONE 2008;3:e3463.
8. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
9. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53.
10. Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010;31:202-9.
11. Stolfi C, Fina D, Caruso R, et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008;75:668-76.
12. Campregher C, Luciani MG, Biesenbach P, et al. The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm Bowel Dis 2010;16:576-82.
13. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602-9.
14. Chu EC, Chai J, Ahluwalia A, et al. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther 2007;25:1443-9.
15. Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 2006;13:202-11.
16. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201:1205-15.
17. Bos CL, Diks SH, Hardwick JCH, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006;27:2371-82.
18. Khare V, Lyakhovich A, Dammann K, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol 2013;85:234-44.
19. Luciani MG, Campregher C, Fortune JM, et al. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007;132:221-35.
20. Honeder C, Campregher C, Zens B, et al. Improvement of replication fidelity by certain mesalazine derivatives. Int J Oncol 2012;40:1331-8.
21. Campregher C, Honeder C, Chung H, et al. Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res 2010;16:1950-6.
22. Gasche C, Goel A, Natarajan L, et al. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005;65:3993-7.
23. Kucherlapati MH, Lee K, Nguyen AA, et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 2010;138:993-1002.e1.
24. Gasche C, Chang CL, Natarajan L, et al. Identification of frame-shift intermediate mutant cells. Proc Natl Acad Sci USA 2003;100:1914-19.
25. Campregher C, Luciani MG, Gasche C. Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut 2008;57:780-7.
26. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 1981;15:57-9.
27. Lang M, Borgmann M, Oberhuber G, et al. Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol Cancer 2013;12:41.
28. Kabbarah O, Mallon MA, Pfeifer JD, et al. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinog 2003;38:155-9.
29. Natarajan L, Berry CC, Gasche C. Estimation of spontaneous mutation rates. Biometrics 2003;59:555-61.
30. Fina D, Franchi L, Caruso R, et al. 5-aminosalicylic acid enhances anchorageindependent colorectal cancer cell death. Eur J Cancer 2006;42:2609-16.
31. Ryan BM, Russel MGVM, Langholz E, et al. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 2003;98:1682-7.
32. Burn J, Bishop DT, Mecklin J-P, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008;359:2567-78.
33. Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081-7.
34. Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 1998;95:11301-6.
35. McIlhatton MA, Tyler J, Kerepesi LA, et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) 2011;4:684-93.
36. Luciani MG, Campregher C, Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007;28:2207-17.
37. Goel A, Chang DK, Ricciardiello L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 2003;9:383-90.
38. Woo CC, Kumar AP, Sethi G, et al. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 2012;83:443-51.
39. Kundu J, Choi BY, Jeong C-H, et al. Thymoquinone induces apoptosis in human colon cancer HCT116cells through inactivation of STAT3 by blocking JAK2- and Src-mediated phosphorylation of EGF receptor tyrosine kinase. Oncol Rep 2014;32:821-8.
40. Reinacher-Schick A, Schoeneck A, Graeven U, et al. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003;24:443-51.
41. Tajima A, Hess MT, Cabrera BL, et al. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004;127:1678-84.
42. Vasen HFA, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.
43. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-73.